Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics
GET POWR RATINGS... FREE!
MRSN POWR Grades
- MRSN scores best on the Growth dimension, with a Growth rank ahead of 62.59% of US stocks.
- The strongest trend for MRSN is in Momentum, which has been heading down over the past 179 days.
- MRSN's current lowest rank is in the Value metric (where it is better than 8.21% of US stocks).
MRSN Stock Summary
- Mersana Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.93% of US listed stocks.
- With a price/sales ratio of 8,164.44, Mersana Therapeutics Inc has a higher such ratio than 99.88% of stocks in our set.
- As for revenue growth, note that MRSN's revenue has grown -94.81% over the past 12 months; that beats the revenue growth of only 0.97% of US companies in our set.
- Stocks that are quantitatively similar to MRSN, based on their financial statements, market capitalization, and price volatility, are CALT, TFFP, VNRX, OTIC, and LXRX.
- Visit MRSN's SEC page to see the company's official filings. To visit the company's web site, go to www.mersana.com.
MRSN Valuation Summary
- MRSN's EV/EBIT ratio is -6.3; this is 121.5% lower than that of the median Healthcare stock.
- Over the past 51 months, MRSN's price/sales ratio has gone up 22705.9.
- Over the past 51 months, MRSN's price/sales ratio has gone up 22705.9.
Below are key valuation metrics over time for MRSN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MRSN | 2021-08-31 | 22718.2 | 5.1 | -7.9 | -6.3 |
| MRSN | 2021-08-30 | 22279.5 | 5.0 | -7.7 | -6.1 |
| MRSN | 2021-08-27 | 21218.2 | 4.8 | -7.4 | -5.7 |
| MRSN | 2021-08-26 | 19213.6 | 4.3 | -6.7 | -5.0 |
| MRSN | 2021-08-25 | 19277.3 | 4.3 | -6.7 | -5.1 |
| MRSN | 2021-08-24 | 18804.5 | 4.2 | -6.5 | -4.9 |
MRSN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRSN has a Quality Grade of D, ranking ahead of 22.8% of graded US stocks.
- MRSN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- ARNA, EYEG, and AGTC are the stocks whose asset turnover ratios are most correlated with MRSN.
The table below shows MRSN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | 1 | -19.265 |
| 2021-03-31 | 0.003 | 1 | -11.244 |
| 2020-12-31 | 0.003 | 1 | -4.878 |
| 2020-09-30 | 0.004 | 1 | -3.132 |
| 2020-06-30 | 0.011 | 1 | -2.130 |
| 2020-03-31 | 0.009 | 1 | -2.198 |
MRSN Price Target
For more insight on analysts targets of MRSN, see our MRSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.67 | Average Broker Recommendation | 1.29 (Strong Buy) |
MRSN Stock Price Chart Interactive Chart >
MRSN Price/Volume Stats
| Current price | $3.33 | 52-week high | $15.34 |
| Prev. close | $3.15 | 52-week low | $2.68 |
| Day low | $3.14 | Volume | 902,800 |
| Day high | $3.36 | Avg. volume | 1,697,033 |
| 50-day MA | $3.80 | Dividend yield | N/A |
| 200-day MA | $6.61 | Market Cap | 322.98M |
Mersana Therapeutics, Inc. (MRSN) Company Bio
Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Latest MRSN News From Around the Web
Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business UpdatesCAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, February 28, 2022 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2021 and provide business updates. T |
Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out forMersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceCAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company’s management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET. A live webcast of the prese |
DCFCW, MRSN and GRTS among after hour moversGainers:Enphase Energy (NASDAQ:ENPH) +16%. Tritium DCFC (NASDAQ:DCFCW) +12%. Leafly Holdings (NASDAQ:LFLY) +11%. Tritium DCFC Limited (NASDAQ:DCFC) +9%. Mersana Therapeutics (NASDAQ:MRSN) +8%. Losers: Varex Imaging (NASDAQ:VREX) -14%. QuinStreet (NASDAQ:QNST) -10%. Ichor Holdings (NASDAQ:ICHR) -6%. Lyft (NASDAQ:LYFT) -6%. Gritstone (NASDAQ:GRTS) -5%.... |
MRSN Price Returns
| 1-mo | -4.31% |
| 3-mo | -24.15% |
| 6-mo | -50.59% |
| 1-year | -76.75% |
| 3-year | -27.45% |
| 5-year | N/A |
| YTD | -46.46% |
| 2021 | -76.63% |
| 2020 | 364.40% |
| 2019 | 40.44% |
| 2018 | -75.17% |
| 2017 | N/A |
Continue Researching MRSN
Want to do more research on Mersana Therapeutics Inc's stock and its price? Try the links below:Mersana Therapeutics Inc (MRSN) Stock Price | Nasdaq
Mersana Therapeutics Inc (MRSN) Stock Quote, History and News - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...